Here’s what you should know:
1. The combined solution is a blood-based test for recurrent tumors circulating in DNA.
2. The test can be conducted by a physician through a “simple blood test.”
3. Qiagen’s Head of Molecular Diagnostics Business Thierry Bernard said in a release the test is a non-invasive monitoring option for colorectal cancer patients.
4. The test is as effective as market standard tests for recurrent colorectal cancer.
5. The companies established a joint venture company, PreAnalytiX GmbH, to develop the test.
More articles on gastroenterology:
Majority of ulcerative colitis patients not achieving clinical, endoscopic remission — 5 key notes
GI leader to know: Dr. Sarah Brendler of the Cascade Endoscopy Center
GI center to know: Cascade Endoscopy Center
